The “norm and practice” of Pharmaceutical companies is to vehemently deny the most serious adverse side effects of their products. This industry’s success in concealing the truth about the serious harm caused by their drugs and vaccines has been aided and abetted . . . Continue reading →
A recent interview on Mad in America (MIA, on May 15th) with professor David Cohen, Ph.D focused on his work on psychiatric coercion. His illuminating insights provide an understanding of how psychiatry gets away with forced treatment with drugs that have clinically . . . Continue reading →
On June 27, 2016, The New York Times reported that New York University medical school “quietly shut down eight studies at its prominent psychiatric research center” and dismissed Dr. Alexander Neumeister, the studies’ lead investigator was the director of the Molecular Imaging . . . Continue reading →
On Friday, April 6, the FDA approved another of Eli Lilly’s "breakthroughs" whose clinical value is questionable (at best). Continue reading →
"The problem of prescription overdose in the military has its parallel in civilian life. The tragic overdose victims in both spheres represent canaries in the coal mine–only the most obvious victims of what has become our national orgy of over using psychotropic drugs." Allen Frances MD Continue reading →
If mentally incapacitated troops are being drugged with dangerous, mind-altering drugs and deployed to battle against their will, how can we say that we have a volunteer army?
"Our systems of mental health care have become too medication focused, and it’s time for a broader approach. History will show that this national shift began this weekend in Portland, Oregon.” Continue reading →
"The risk was greater for individuals prescribed atypical rather than conventional drugs."
Antipsychotic Drugs and Risk of Venous Thromboembolism: Nested Case-Control Study BMJ
According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel . . . Continue reading →